Clinical trials: Recurrence of Clostridium Difficile Infection
Clostridium Difficile Infection, Health Care Associated Infection
Natural History of Clostridioides Difficile Infection
Aim: To investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of Clostridioides difficile infection (CDI).
- Conditions
- Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection
- Trial name
- NCT04801862
- Where
- 15 sites in Spain
- Volunteers
- 750 people
- Sponsor
- Hospital Universitario de Valme
Enterocolitis, Recurrent Clostridium Difficile Infection
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
Fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile infection (RCDI) has traditionally been offered as fecal slurry administered by enema, nasogastric tube or endoscopy.
- Trial name
- NCT03353506
- Testing
- LFMT, LSFF
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Dina Kao
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving…
- Conditions
- Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea
- Trial name
- NCT03462459
- Testing
- Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 79 people
- Sponsor
- University of Wisconsin, Madison
Clostridium Difficile Infections
Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma
The increasing inappropriate use of antimicrobials, in addition to increasing selective pressure and inducing environmental resistance, is also a risk factor for the development of Clostridioides difficile infection (CDI).
- Trial name
- NCT06107569
- Testing
- Fecal microbiota transplant (Promicrobioma), Antibiotic
- Volunteers
- 24 people
- Sponsor
- Hospital Universitario Evangelico de Curitiba
Enterocolitis Clostridium Difficile Recurrent
FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff
Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully.
- Trial name
- NCT02254811
- Testing
- Fecal Microbiota Transplant
- Where
- 2 sites in Canada
- Volunteers
- 116 people
- Sponsor
- University of Alberta
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile…
- Conditions
- Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI), Fecal Microbiota Therapy (FMT), Irritable Bowel Syndrome (IBS)
- Trial name
- ORAL-LYO-FMT (NCT06948461)
- Testing
- ORAL-LYO-FMT
- Volunteers
- 63 people
- Sponsor
- PharmaPlanter Technologies Inc
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.
- Trial name
- NCT04000555
- Testing
- Oral Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Clostridium Difficile Infection
Treatment of Recurrent Clostridium Difficile Infection With RBX7455
The purpose of this study is to demonstrate the efficacy and safety of RBX7455 for the treatment of recurrent CDI in subjects who have had at least one recurrence after a primary episode (i.e., at least two episodes) and have…
- Trial name
- NCT02981316
- Testing
- RBX7455
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Clostridioides Difficile Infection
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days. The purpose of this study is to provide access to SER-109 for adult subjects with recurrent Clostridioides Difficile Infection (RCDI)…
- Trial name
- NCT02437500
- Testing
- SER-109
- Sponsor
- Seres Therapeutics, Inc.
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Recurrent C. Difficile Infection
A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)
This is a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4).
- Trial name
- PRISM4 (NCT05153499)
- Testing
- CP101
- Where
- 68 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Finch Research and Development LLC.
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
The purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent Clostridium difficile (C. diff) infection of the colon.
- Trial name
- NCT03562741
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Krunal Patel
Clostridium Difficile Infection Recurrence
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and…
- Trial name
- BEZLO (NCT03880539)
- Testing
- bezlotoxumab, Vancomycin Oral
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Kansas Medical Center
Clostridioides Difficile Infection
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling.
- Trial name
- NCT07613645
- Testing
- Health counseling sessions, Diet (control diet), Diet (experimental diet)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Clostridioides Difficile Infection
Ursodeoxycholic Acid in C. Difficile Infection
The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid
- Trial name
- NCT05526807
- Testing
- Ursodeoxycholic acid
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Clostridium Difficile Infection
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
MET-2 clinical study is an Open label, single center, multiple dose pilot study of 19 patients. The study is designed to measure the resolution of diarrhea as well as the feasibility of administration and safety of MET-2 for the…
- Trial name
- NCT02865616
- Testing
- MET-2, Vancomycin
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- NuBiyota
Recurrence of Clostridium Difficile Infection
REBYOTA™ Prospective Registry
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting.
- Trial name
- ROAR (NCT05835219)
- Testing
- REBYOTA™
- Where
- 42 sites in United States
- Volunteers
- 145 people
- Sponsor
- Ferring Pharmaceuticals
Clostridium Difficile Infection
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
MK-3415A is the combination of monoclonal antibodies to Clostridium (C.) difficile toxin A (MK-3415) and toxin B (MK-6072). This study will investigate whether: 1) treatment with MK-6072 or MK-3415A in addition to standard of…
- Trial name
- MODIFY II (NCT01513239)
- Testing
- MK-6072, MK-3415A, SOC
- Volunteers
- 1,203 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Clostridium Difficile Infection
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of…
- Trial name
- NCT03973697
- Testing
- Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.